The systemically acting intranasally administered biologics (proteins and peptides) under clinical investigation as enrolled at clinicaltrials.gov was listed by Rohrer et al
However, even then, they are not usually toxic
After all, there are plenty of people who have obesity but dont have any evidence of heart disease or diabetes
Toloza E, Hunt KK, Swisher SG , Rhoades K, McBride W, Lau R, Atha T, Pang S, Belldegrun A, Glaspy J, Economou J
A medication that reduces appetite can compound this by making it harder to meet the increased nutritional demands of breastfeeding
The standard dosing schedule starts at 2.5 mg weekly and escalates every four weeks: Weeks 14: 2.5 mg weekly (initiation dose to acclimate to GLP-1/GIP receptor activation) Weeks 58: 5 mg weekly Weeks 912: 7.5 mg weekly (optional intermediate step) Weeks 1316: 10 mg weekly Weeks 1720: 12.5 mg weekly (optional intermediate step) Week 21 onward: 15 mg weekly (maximum maintenance dose) Tirzepatide is injected subcutaneously just under the skin using a pre-filled pen or syringe
